CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Advanced Tissue Sciences is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Advanced Tissue Sciences
10933 North Torrey Pines Road
Phone: (858) 713-7300p:858 713-7300 La Jolla, CA  92037  United States Ticker: ATISZ ATISZ

This company's Plan of Liquidation went into effect on 3/31/2003
This company ceased filing statements with the SEC on 4/1/2003.
This company is no longer actively traded on any major stock exchange.

Business Summary
Advanced Tissue Sciences, Inc. (ATS) is conducts business in the field of tissue engineering, using its patented technology to develop human-based tissue products for a variety of therapeutic applications. ATS uses principles of cell biology, bioengineering, biochemistry, polymer science and transplant science in order to culture living human cells, either within, "in vivo," or outside, "ex vivo," the human body, in a way that allows the cells to develop and assemble into a functioning three-dimensional tissue. With this human-based tissue development technology, the Company has successfully replicated a number of tissues that are being developed for the purpose of replacing, repairing or restoring diseased, damaged or aging tissue and organs. In October 2002, the Company filed a voluntary petition for reorganization under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of California.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/200212/31/2001-YesYes--

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Acting Chief Financial Officer Andrew J.Buckland 45 11/13/2002 11/13/2002
Joseph R.Kletzel 56 8/1/2000 5/1/1998
Charles E.Anderson 53 10/1/1998 10/1/1997
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 226 (As of 12/31/2001)
Outstanding Shares: 73,154,753 (As of 11/18/2002)
Shareholders: 1,434
Stock Exchange: OTC
Federal Tax Id: 141701513
Fax Number: (858) 713-7400


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023